30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Seikagaku

(FY1Q13, ended 6/30/13)

¥7,647MM (~US $78MM), +14%

  • Growth attributed in part to Gel-One sales
  • U.S. Supartz sales fell due to remaining impact of reimbursement restrictions, while Artz sales in China increased following physician education activities